Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.60 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700617 | 0.80 | CHRNA7 (0.52) | CHRNA7HTR3ANPC1RAB9A | |
| SCHEMBL4701301 | 0.79 | CHRNA7 (0.57) | CHRNA7HTR3ANPC1RAB9ACHRNA3 | |
| SCHEMBL4704581 | 0.79 | CHRNA7 (0.57) | CHRNA7HTR3ANPC1RAB9ACHRNA3 | |
| SCHEMBL4703034 | 0.79 | CHRNA7 (0.47) | CHRNA7HTR3AL3MBTL3L3MBTL1 | |
| SCHEMBL4701453 | 0.78 | ALDH1A1 (0.56) | CHRNA7HTR3ANPC1RAB9AL3MBTL1 | |
| SCHEMBL4704311 | 0.77 | CHRNA7 (0.64) | CHRNA7HTR3A | |
| SCHEMBL4700217 | 0.76 | KDM4E (0.56) | CHRNA7HTR3ANPC1RAB9A | |
| SCHEMBL4700316 | 0.76 | CHRNA7 (0.70) | CHRNA7HTR3ANPC1RAB9ACHRNA3 | |
| SCHEMBL4701548 | 0.76 | CHRNA7 (0.62) | CHRNA7HTR3ANPC1RAB9ACHRNA3 | |
| SCHEMBL4701573 | 0.76 | HDAC3 (0.48) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | claimed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | claimed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | CHRNA1, CHRNB1, CHRNA2 | CHRNA7 6/4885HTR3A 162/4885NPC1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.